Bull’s Eye Report: Pharmacyclics (PCYC)

Buy PCYC at current levels

   

At StateoftheMarkets.com, we strive to “own the best and ignore the rest” in our equity portfolios. Toward this end, each day we search our database for a “top stock” (a top rated company in terms of earnings strength as well as company and industry performance) that presents a strong technical “set up” and a good entry point.

In short, when our equity team is looking to add a stock to one of our portfolios, the “bull’s eye” stock shown below is generally their first choice.

Company Symbol Industry Stock Rating YTD% Gain S.T. Stop Loss
Pharmacyclics Inc PCYC Biotechnology 9.9 +24.50% $72.73

Why We Like The Stock:

Pharmacyclics Inc. (NASDAQ:PCYC) is our most compelling buy today due to the fact that it is a top rated stock (in terms of earnings strength and company/industry performance) with a positive technical set-up. Biotechnology has been hot this year, as evidenced in strong charts like Onyx Pharmaceuticals (NASDAQ:ONXX), Seattle Genetics (NASDAQ:SGEN), Medivation (NASDAQ:MDVN), and the SPDR Biotech ETF (NYSE:XBI). PCYC has been consolidating early 2013 gains since mid March after topping off around $95. Currently, the stock has been hovering above the $75 area and looks to be basing. This morning, PCYC crossed above its 5-day moving average. If now is the time that this biotech stock turns the corner, we would absolutely be buyers at the current price. PCYC has an extremely high short-term upside to $95 (+20.8%), and with a tight leash at $75, the downside on this trade is limited. So long as it holds the $75 level on a closing basis, we would take a shot here with PCYC.

We Would Be Buyers:

At the current price (~$78.63).

Company Profile:

Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company’s clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases.

Stock Rating: 9.9

The Stock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 – 10 with 10 being the highest.

Pharmacyclics – Last Three Months

PCYC 1 Bulls Eye Report: Pharmacyclics (PCYC)

Pharmacyclics – Last 12 Months

PCYC 2 Bulls Eye Report: Pharmacyclics (PCYC)

Pharmacyclics – Last Five Years

PCYC 3 Bulls Eye Report: Pharmacyclics (PCYC)

Looking to trade the Bull’s Eye stock picks? Click here to download our free Special Report, “How We Identify Our “Bull’s Eye” Picks & How You Can Profit Trading Them”

At the time of publication the editor and affiliated companies own the following positions: None

Note: Positions may be bought or sold while this publication is in circulation without notice.


Article printed from InvestorPlace Media, http://investorplace.com/247trader/bulls-eye-report-pharmacyclics-pcyc/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.